Summary
Stryker Corporation reported solid financial results for the first quarter of 2015, with net sales increasing by 3.2% to $2.379 billion. This growth was driven by a combination of increased unit volume and strategic acquisitions, though partially offset by unfavorable foreign currency exchange rates and pricing changes. Net earnings saw a significant jump of 220.0% to $224 million, or $0.58 per diluted share, largely due to a substantial reduction in recall charges compared to the prior year. The company continues to invest in research and development, with R&D expenses remaining stable as a percentage of net sales. Management highlighted disciplined expense management in selling, general, and administrative costs. Despite some headwinds from currency fluctuations and a slight increase in cost of sales as a percentage of net sales, Stryker demonstrated strong operational performance and positive momentum heading into the rest of the fiscal year. The company also announced a new $2 billion share repurchase program, signaling confidence in its financial position and commitment to returning value to shareholders.
Financial Highlights
50 data points| Revenue | $2.38B |
| Cost of Revenue | $826.00M |
| Gross Profit | $1.55B |
| R&D Expenses | $152.00M |
| SG&A Expenses | $892.00M |
| Operating Expenses | $1.15B |
| Operating Income | $406.00M |
| Net Income | $224.00M |
| EPS (Basic) | $0.59 |
| EPS (Diluted) | $0.58 |
| Shares Outstanding (Basic) | 378.90M |
| Shares Outstanding (Diluted) | 383.50M |
Key Highlights
- 1Consolidated net sales increased 3.2% to $2.379 billion, with organic growth of 5.6% in constant currency.
- 2Net earnings surged by 220.0% to $224 million ($0.58/share) compared to $70 million ($0.18/share) in the prior year, primarily due to significantly lower recall charges.
- 3Recall charges related to hip stems decreased substantially from $344 million in Q1 2014 to $54 million in Q1 2015.
- 4The MedSurg segment showed the strongest reported sales growth at 4.6%, driven by a 13.5% increase in Medical products.
- 5The company announced a new $2 billion share repurchase program, alongside ongoing repurchases under existing programs, totaling $130 million in the quarter.
- 6Operating cash flow improved significantly to $380 million from $209 million in the prior year, supported by higher net earnings and improved working capital management.
- 7The effective income tax rate increased to 40.6% from 34.5%, attributed to discrete tax items related to the establishment of a European regional headquarters.